Webinar Recording
Vimseltinib: A New Treatment Option for Tenosynovial Giant Cell Tumor (TGCT)
Recorded on: March 31, 2025
Gain a deep understanding of the newly approved oral CSF1R inhibitor, vimseltinib, for Tenosynovial Giant Cell Tumor (TGCT) and review pivotal data from the MOTION trial.
Gina D’Amato, MD, and Solange Sierra, APRN, MSN, FNP-BC (University of Miami Sylvester Comprehensive Cancer Center) will share insight into:
- Pivotal data from the MOTION trial
- Where this novel therapy fits in the TGCT treatment landscape
- How to manage side effects effectively
- Ways to support patients through education, access, and coordinated care
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.